BioNTech (NASDAQ:BNTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $107.00 price target on the stock.

Several other analysts have also issued reports on BNTX. BMO Capital Markets reduced their target price on BioNTech from $127.00 to $123.00 and set an outperform rating on the stock in a report on Thursday, March 21st. Canaccord Genuity Group reissued a buy rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. Oppenheimer assumed coverage on shares of BioNTech in a research report on Friday, January 5th. They issued a market perform rating for the company. UBS Group reduced their price target on shares of BioNTech from $110.00 to $101.00 and set a neutral rating on the stock in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research report on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus price target of $120.40.

BioNTech Price Performance

Shares of BioNTech stock opened at $86.40 on Wednesday. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $20.54 billion, a price-to-earnings ratio of 20.97 and a beta of 0.23. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The company has a 50-day simple moving average of $91.49 and a two-hundred day simple moving average of $97.57.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Analysts forecast that BioNTech will post -1.67 EPS for the current year.

Institutional Trading of BioNTech

A number of hedge funds have recently added to or reduced their stakes in the stock. Harding Loevner LP acquired a new stake in shares of BioNTech during the 4th quarter valued at $410,984,000. Baillie Gifford & Co. raised its position in BioNTech by 15.5% in the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock valued at $934,612,000 after purchasing an additional 1,152,541 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of BioNTech by 4,861.2% during the first quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock valued at $1,531,000 after purchasing an additional 952,932 shares in the last quarter. BlackRock Inc. grew its holdings in shares of BioNTech by 25.9% during the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after purchasing an additional 331,101 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of BioNTech in the first quarter valued at approximately $42,711,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.